1. Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline;Daly;J. Clin. Oncol.,2022
2. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group;Pignon;J. Clin. Oncol.,2008
3. Forde, P.M., et al., Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N. Engl. J. Med., 2022. 386(21): p. 1973-1985doi.org/10.1056/NEJMoa2202170.
4. Provencio, M., et al., Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial. Lancet Oncol, 2020. 21(11): p. 1413-1422doi.org/10.1016/s1470-2045(20)30453-8.
5. Rothschild, S.I., et al., SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-Small-Cell Lung Cancer-A Multicenter Single-Arm Phase II Trial. J. Clin. Oncol., 2021. 39(26): p. 2872-2880doi.org/10.1200/jco.21.00276.